Acute Myelogenous Leukemia (AML) Clinical Trial
Official title:
Pilot Trial of Two Dose Levels of Thymoglobulin as Part of a Myeloablative-Conditioning for a Human Leukocyte Antigen (HLA) Identical Matched Related Donor (MRD) Stem Cell Transplant (SCT) With Cyclosporine (CSa) as Post-transplant Graft vs. Host Disease (GvHD) Prophylaxis
This study involves the use of a drug called Thymoglobulin, which is approved in the USA to
treat kidney transplant rejection and in Canada to treat and to prevent kidney transplant
rejection. Thymoglobulin is not approved for the treatment or prophylaxis of graft versus
host disease in bone marrow transplantation. This study is to evaluate two (2) doses of
Thymoglobulin and its safety and effectiveness when used with a "myeloablative" conditioning
regimen prior to receiving a stem cell transplant (also called bone marrow transplantation)
from a matched, related donor.
A myeloablative regimen is typically composed of chemotherapy and radiation and destroys the
subject's existing bone marrow.
Subjects meeting all inclusion and exclusion criteria and who have a relative with matching
(genetically similar) stem cells who are also willing to donate them (i.e.
matched-related-donor) are eligible to participate in this study. Following myeloablative
therapy, the donor's cells are then transplanted (i.e. infused) into the subject's blood
stream.
One of the most common complications of this type of transplant is graft-versus-host disease
(GvHD). This is a condition where the transplanted donor cells attack the transplant
recipient's body. Treatments, such as cyclosporine, are used to minimize the risk of GvHD
following stem cell transplantation.
To enter this study, subjects must be having a matched-related donor stem cell transplant.
If a subject qualifies for entry into this study, he/she will be assigned to receive
Thymoglobulin at a dose of 4.5 mg/kg or 8.5 mg/kg. The treatment assignment is random and is
not chosen by the subject or their physician.
Subjects are admitted to the hospital for the transplant procedure and are treated with
Thymoglobulin over 3-5 days just prior to receiving the donor stem cells. The subject will
also receive standard GvHD prophylaxis with cyclosporine. Methotrexate, which is commonly
used by transplant centers to minimize the risk of GvHD, will not be used in this study.
Subjects will be monitored during treatment with Thymoglobulin and during the transplant
hospitalization. Additional subject monitoring occurs at month 1, 100 days and 6 months
following the transplant.
Approximately 60 study subjects from approximately 14 transplant centers in the United
States and Canada will be enrolled.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00528983 -
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
|
Phase 1 | |
Completed |
NCT01221857 -
Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies
|
Phase 1/Phase 2 | |
Terminated |
NCT01451437 -
Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649)
|
Phase 1 | |
Completed |
NCT01885897 -
IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT
|
Phase 1/Phase 2 | |
Recruiting |
NCT05884333 -
Cord Blood Transplant in Adults With Blood Cancers
|
Phase 2 | |
Terminated |
NCT01873495 -
Omacetaxine for Consolidation and Maintenance
|
Phase 2 | |
Terminated |
NCT03600909 -
A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia
|
Phase 2 | |
Active, not recruiting |
NCT02061800 -
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
|
Phase 1/Phase 2 | |
Terminated |
NCT01113502 -
Eltrombopag in Elderly Acute Myelogenous Leukemia (AML)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT00943553 -
A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects
|
Phase 2 | |
Terminated |
NCT01050764 -
Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells
|
Phase 1/Phase 2 | |
Terminated |
NCT00672152 -
A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation
|
Phase 1 | |
Recruiting |
NCT03260101 -
Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study
|
||
Terminated |
NCT02200380 -
A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs
|
Phase 2 | |
Active, not recruiting |
NCT02240537 -
Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer
|
Phase 1 | |
Completed |
NCT01527838 -
Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit
|
Phase 1 | |
Terminated |
NCT00779480 -
Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002)
|
Phase 1 | |
Completed |
NCT01768845 -
Unrelated Umbilical Cord Blood (UBC)Transplantation
|
N/A | |
Terminated |
NCT01265199 -
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
|
Phase 1 | |
Completed |
NCT02793544 -
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 |